Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells

Products & Services
Catalog
- PepMix™ Peptide Pools
  PepMix™ Peptide Pools
  Pools of overlapping peptides from antigenic proteins for T-cell stimulation, T-cell expansion in T-cell assays such as ELISPOT, ICS or Flow Cytometry, e.g. for immune monitoring.
- Transduction Enhancer
  
  Transduction Enhancer
  Protransduzin™ the highly efficient transduction enhancer increases viral gene transfer in pre-clinical and clinical applications, such as ex vivo gene therapy and CAR-T cell development.
- Antigen Peptides
  - COVID-19 Antigen Peptides
  - Further Antigen Peptides
  Antigen Peptides
  Antigen peptides represent specific epitopes for stimulation of T cells in T cell assays such as ELISPOT. We offer the corresponding MHC multimer for each antigen peptide. Antigens from different pathogens are available as well as tumor associated antigens.
- MHC Multimers
  MHC Multimers
  MHC Multimers for reproducible detection, enumeration and isolation of antigen-specific T cells with disease specific peptides.
- Proteomics Peptides & Kits
  Proteomics Peptides & Kits
  Peptide sets and pools, as well as assay standardization kits are available with stable isotope labeled or unlabeled proteotypic peptides for mass-spectrometry based proteomics such as MRM assays.
- RepliTope™ Peptide Microarrays
  RepliTope™ Peptide Microarrays
  Peptide microarrays that display overlapping peptide scans through antigens from infectious organisms or tumor associated antigens for antibody or serum profiling.
- Chelate Peptides (DOTA)
  
  Chelate Peptides (DOTA)
  DOTA is linked to molecules that have affinity for various structures (e.g. somatostatin receptors in neuroendocrine tumors). The resulting compounds can be bound to radionuclided and are used with a number of radioisotopes in cancer therapy and diagnosis
- Cosmetic Peptides (DPRA Peptides)
  
  Cosmetic Peptides
  Cosmetic Peptides such as Lysine and Cysteine Peptide are used for DPRA (Direct Peptide Reactivity Assay) for Skin Sensitization Testing. The DPRA measures the reaction of a chemical with synthetic peptides containing Cysteine (Ac‑RFAACAA‑COOH) or Lysine (Ac‑RFAAKAA‑COOH) to assess its sensitization potency. For research use only!
- Abeta & Prion Peptides
  - Amyloid Beta A4 Peptides
  - Major Prion Peptides
  Abeta & Prion Peptides
  Purified, fully analyzed, high quality peptides, synthesized from the peptide experts for Alzheimers and prion research.
- Assay Services
  
  Assay Services
  We offer our extensive know-how and experience in peptide microarray incubation & data evaluation as full-service packages for many applications.
- Enzyme Substrates
  Enzyme Substrates
  Large collections of peptidic enzyme substrates in microtiter plates or displayed on microarrays for screening and enyzme profiling.
- Histone Peptide Tools
  Histone Peptide Tools
  Our histone peptide library is the largest on the market and available as Peptide ELISA, Peptide Microarray or sets of histone peptides
Contract Research
Company
- - JPT has a work force of >100 highly trained and skilled employees. 30 of our co-workers hold a university degree and 20 have a PhD in natural sciences.
News & Publications
Support & Contact
- - We take pride in our competent service and swift response. Please do not hesitate to contact us for further information. We also very much welcome your feedback and comments.

Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells

Sung et al., EBioMedicine (2017) - PMID: 28803740

Product(s) used in this publication: PepMix™ Peptide Pools

Abstract

Latently humanimmunodeficiencyvirus (HIV)-infected cells are transcriptionally quiescent and invisible to clearance by the immune system. To demonstrate that the latency reversing agent vorinostat (VOR) induces a window of vulnerability in the latentHIVreservoir, defined as the triggering of viral antigen production sufficient in quantity and duration to allow for recognition and clearance of persisting infection, we developed a latency clearance assay (LCA). The LCA is a quantitative viral outgrowth assay (QVOA) that includes the addition of immune effectors capable of clearing cells expressing viral antigen. Here we show a reduction in the recovery of replication-competentvirus from VOR exposed resting CD4 Tcells following addition of immune effectors for a discrete period.

Search

All Our Publications